General Atlantic

To add a bio or update investment portfolio, please click update information.

Investment Portfolio

Verdiva Bio secures £333.5m Series A led by Forbion and General Atlantic to develop next-gen weight loss therapies

9 Jan 2025

Verdiva Bio secures £333.5m Series A led by Forbion and General Atlantic to develop next-gen weight loss therapies

Verdiva Bio develops next-generation obesity and metabolic disease therapies, advancing oral and injectable treatment candidates to improve access, adherence and long-term outcomes.

General Atlantic

- Life Sciences
generalatlantic.com
Update Information

More venture news

Combat Medical
12 Mar 2026
Combat Medical raises a £2.6m Series A led by T&J Meyer Family Foundation for hard-to-treat bladder cancer
Series AHealth
Outpost
10 Mar 2026
Outpost unlocks £13m Series A led by Ribbit for cross-border payments and tax compliance infrastructure
Series AFintech
4 Mar 2026
Shellworks raises £11m Series A led by Alter Equity for biodegradable packaging made from microbial fermentation
Series ASupply Chain

General Atlantic

Investment Portfolio

Verdiva Bio secures £333.5m Series A led by Forbion and General Atlantic to develop next-gen weight loss therapies

More venture news

Combat Medical raises a £2.6m Series A led by T&J Meyer Family Foundation for hard-to-treat bladder cancer

Outpost unlocks £13m Series A led by Ribbit for cross-border payments and tax compliance infrastructure

Shellworks raises £11m Series A led by Alter Equity for biodegradable packaging made from microbial fermentation